Alphamab Oncology (HKG:9966) said JSKN003 received approval from the Center for Drug Evaluation of China's National Medical Products Administration to initiate a phase III clinical study, according to Friday filing with the Hong Kong bourse.
JSKN003 is a HER2-targeting ADC (antibody-drug conjugate) that combines a topoisomerase I inhibitor with KN026 (a humanized anti-HER2 bispecific antibody) used to treat tumors. The drug linker is attached specifically to the antibody's N-glycosylation site using glycoside-specific conjugation, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.